WO2016140118A1 - 放射性ヨウ素標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 - Google Patents
放射性ヨウ素標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 Download PDFInfo
- Publication number
- WO2016140118A1 WO2016140118A1 PCT/JP2016/055356 JP2016055356W WO2016140118A1 WO 2016140118 A1 WO2016140118 A1 WO 2016140118A1 JP 2016055356 W JP2016055356 W JP 2016055356W WO 2016140118 A1 WO2016140118 A1 WO 2016140118A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bip
- radioactive iodine
- compound
- group
- salt
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 76
- 229910052740 iodine Inorganic materials 0.000 title claims abstract description 61
- 239000011630 iodine Substances 0.000 title claims abstract description 46
- -1 PYRIDO[1,2-a]BENZOIMIDAZOLE DERIVATIVE COMPOUND Chemical class 0.000 title abstract description 11
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 title description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 59
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims description 73
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 25
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 12
- 239000012217 radiopharmaceutical Substances 0.000 claims description 8
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 8
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 claims description 4
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical group IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 210000005013 brain tissue Anatomy 0.000 description 26
- 102000013498 tau Proteins Human genes 0.000 description 26
- 108010026424 tau Proteins Proteins 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- FODVQKYUAIWTKY-UHFFFAOYSA-N pyrido[1,2-a]benzimidazole Chemical compound C1=CC=CN2C3=CC=CC=C3N=C21 FODVQKYUAIWTKY-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000009825 accumulation Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- 210000003478 temporal lobe Anatomy 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012156 elution solvent Substances 0.000 description 12
- 238000012744 immunostaining Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 210000001652 frontal lobe Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- GQXDDOJKEBMGPF-UHFFFAOYSA-N tributyl-(3-phenylpyrido[1,2-a]benzimidazol-7-yl)stannane Chemical compound C(CCC)[Sn](C1=CC2=C(N3C(=N2)C=C(C=C3)C2=CC=CC=C2)C=C1)(CCCC)CCCC GQXDDOJKEBMGPF-UHFFFAOYSA-N 0.000 description 6
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000011888 autopsy Methods 0.000 description 5
- 238000000376 autoradiography Methods 0.000 description 5
- 229940126142 compound 16 Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000009206 nuclear medicine Methods 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- JVZRCNQLWOELDU-UHFFFAOYSA-N 4-Phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 description 4
- LHQNJQVMDLEMJR-UHFFFAOYSA-N 7-bromo-3-phenylpyrido[1,2-a]benzimidazole Chemical compound BrC1=CC2=C(N3C(=N2)C=C(C=C3)C2=CC=CC=C2)C=C1 LHQNJQVMDLEMJR-UHFFFAOYSA-N 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- REDSKZBUUUQMSK-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC.CCCC[Sn](CCCC)CCCC REDSKZBUUUQMSK-UHFFFAOYSA-N 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- SRJGEESSPMIDAR-UHFFFAOYSA-N 1-iodopyrido[1,2-a]benzimidazole Chemical compound IC1=CC=CC=2N1C1=C(N=2)C=CC=C1 SRJGEESSPMIDAR-UHFFFAOYSA-N 0.000 description 3
- KRIILKQTJUOQCJ-UHFFFAOYSA-N 2-bromo-4-phenylpyridine Chemical compound C1=NC(Br)=CC(C=2C=CC=CC=2)=C1 KRIILKQTJUOQCJ-UHFFFAOYSA-N 0.000 description 3
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 3
- BOCDRGHVWAIPSQ-UHFFFAOYSA-N 3-(4-iodophenyl)pyrido[1,2-a]benzimidazole Chemical compound IC1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 BOCDRGHVWAIPSQ-UHFFFAOYSA-N 0.000 description 3
- SIDSDGLOKXLQJW-UHFFFAOYSA-N 3-iodopyrido[1,2-a]benzimidazole Chemical compound IC1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 SIDSDGLOKXLQJW-UHFFFAOYSA-N 0.000 description 3
- JHEXBFYUDVVVHD-UHFFFAOYSA-N 7-iodo-3-phenylpyrido[1,2-a]benzimidazole Chemical compound IC1=CC2=C(N3C(=N2)C=C(C=C3)C2=CC=CC=C2)C=C1 JHEXBFYUDVVVHD-UHFFFAOYSA-N 0.000 description 3
- VXWYDKZHSAWIMS-UHFFFAOYSA-N 7-iodopyrido[1,2-a]benzimidazole Chemical compound IC1=CC2=C(N3C(=N2)C=CC=C3)C=C1 VXWYDKZHSAWIMS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- PXMFOOVGCVKNSR-UHFFFAOYSA-N IC1=CC(=CC=2N1C1=C(N2)C=CC=C1)C1=CC=CC=C1 Chemical compound IC1=CC(=CC=2N1C1=C(N2)C=CC=C1)C1=CC=CC=C1 PXMFOOVGCVKNSR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- FVAUCKIRQBBSSJ-FXMLPJBTSA-M sodium;iodine-125(1-) Chemical compound [Na+].[125I-] FVAUCKIRQBBSSJ-FXMLPJBTSA-M 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- WRTAZRGRFBCKBU-UHFFFAOYSA-N 2,5-dibromoaniline Chemical compound NC1=CC(Br)=CC=C1Br WRTAZRGRFBCKBU-UHFFFAOYSA-N 0.000 description 2
- JHCOGBPILQVHLW-UHFFFAOYSA-N C(CCC)[Sn](C1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1)(CCCC)CCCC Chemical compound C(CCC)[Sn](C1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1)(CCCC)CCCC JHCOGBPILQVHLW-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C12)C=C(*)*=*C1N=C1N2C=CC(*)=C1 Chemical compound CC(C12)C=C(*)*=*C1N=C1N2C=CC(*)=C1 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910020175 SiOH Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005831 deiodination reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UDBYWUXMINMNEN-UHFFFAOYSA-N tributyl(pyrido[1,2-a]benzimidazol-7-yl)stannane Chemical compound C(CCC)[Sn](C1=CC2=C(N3C(=N2)C=CC=C3)C=C1)(CCCC)CCCC UDBYWUXMINMNEN-UHFFFAOYSA-N 0.000 description 2
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- DGAROTKDMYJPCD-UHFFFAOYSA-N 1h-benzimidazole;pyrimidine Chemical class C1=CN=CN=C1.C1=CC=C2NC=NC2=C1 DGAROTKDMYJPCD-UHFFFAOYSA-N 0.000 description 1
- QQLPPRIZUPEKMV-UHFFFAOYSA-N 2-(2-phenylethenyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C=CC1=CC=CC=C1 QQLPPRIZUPEKMV-UHFFFAOYSA-N 0.000 description 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical class O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 description 1
- BOCDRGHVWAIPSQ-GSLGWBAQSA-N 3-(4-(123I)iodanylphenyl)pyrido[1,2-a]benzimidazole Chemical compound [123I]C1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 BOCDRGHVWAIPSQ-GSLGWBAQSA-N 0.000 description 1
- BOCDRGHVWAIPSQ-HGTLKWEASA-N 3-(4-(125I)iodanylphenyl)pyrido[1,2-a]benzimidazole Chemical compound [125I]C1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 BOCDRGHVWAIPSQ-HGTLKWEASA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YWBSQLFNAWUXHX-UHFFFAOYSA-N 3-bromopyrido[1,2-a]benzimidazole Chemical compound BrC1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 YWBSQLFNAWUXHX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- VXWYDKZHSAWIMS-SCLBOMOGSA-N 7-(123I)iodanylpyrido[1,2-a]benzimidazole Chemical compound [123I]C=1C=CC2=C(N=C3N2C=CC=C3)C=1 VXWYDKZHSAWIMS-SCLBOMOGSA-N 0.000 description 1
- WIJHDYJWBJCOKR-UHFFFAOYSA-N 7-bromopyrido[1,2-a]benzimidazole Chemical compound BrC1=CC2=C(N3C(=N2)C=CC=C3)C=C1 WIJHDYJWBJCOKR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- CWDXATHTOVQXJH-UHFFFAOYSA-N BrC1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 Chemical compound BrC1=CC=C(C=C1)C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1 CWDXATHTOVQXJH-UHFFFAOYSA-N 0.000 description 1
- FTPAKXLWQWURJZ-UHFFFAOYSA-N C(CCC)[Sn](C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1)(CCCC)CCCC Chemical compound C(CCC)[Sn](C1=CC=2N(C=C1)C1=C(N=2)C=CC=C1)(CCCC)CCCC FTPAKXLWQWURJZ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YPPAUKJMFPNOLS-HGTLKWEASA-N [125I]C(C=C1)=CC=C1C1=CC=CC2=NC(C=CC=C3)=C3N12 Chemical compound [125I]C(C=C1)=CC=C1C1=CC=CC2=NC(C=CC=C3)=C3N12 YPPAUKJMFPNOLS-HGTLKWEASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010576 medium-pressure preparative liquid chromatography Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910001511 metal iodide Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- FVAUCKIRQBBSSJ-VVUPZWBASA-M sodium;iodine-123(1-) Chemical compound [Na+].[123I-] FVAUCKIRQBBSSJ-VVUPZWBASA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the present invention relates to a radioiodine-labeled pyrido [1,2-a] benzimidazole derivative compound or a salt thereof, and a radiopharmaceutical containing the same.
- senile plaques mainly composed of amyloid ⁇ protein (A ⁇ ) and neurofibrillary tangles (NFT) mainly composed of tau protein are observed. Since the accumulation of NFT shows a higher correlation with clinical symptoms than SP, recently, development of a radiomolecular imaging probe for nuclear medicine diagnosis targeting tau protein has attracted attention.
- Patent Document 1 describes a radioiodine-labeled compound of rhodanine and thiohydantoin derivatives having affinity for tau protein.
- Patent Documents 2 and 3 describe compounds having binding properties to both A ⁇ and tau protein. Specifically, Patent Document 2 describes a radioiodine-labeled compound having styrylbenzimidazole as a mother nucleus, and Patent Document 3 describes benzimidazole pyrimidines and the like.
- Patent Documents 1 to 3 have room for improvement as tau protein-selective in vivo imaging agents.
- the present invention has been made in view of the above circumstances, and an object thereof is to provide a novel tau imaging agent capable of selectively imaging in vivo tau protein non-invasively by a nuclear medicine technique. .
- the inventors of the present invention have newly shown that non-specific accumulation in white matter can be suppressed while maintaining selective binding to tau protein with a radioactive iodine-labeled pyrido [1,2-a] benzimidazole derivative compound. As a result, the present invention has been completed.
- One embodiment of the present invention provides a radioactive iodine-labeled compound represented by the following general formula (1) or a salt thereof.
- R 1 when R 1 is a hydrogen atom, R 2 is a radioactive iodine atom or a radioiodinated phenyl group, and when R 1 is a radioactive iodine atom, R 2 is a hydrogen atom or a phenyl group. It is.
- Another aspect of the present invention provides a radiopharmaceutical comprising the above-mentioned radioiodine-labeled compound or a salt thereof.
- an Alzheimer's disease diagnostic agent comprising the above-mentioned radioactive iodine-labeled compound or a salt thereof.
- Another aspect of the present invention provides a compound represented by the following general formula (2) or a salt thereof.
- R 4 when R 3 is a hydrogen atom, R 4 is a trialkylstannyl group, a trialkylsilyl group, a trialkylstannylated phenyl group, or a trialkylsilylated phenyl group, When 3 is a trialkylstannyl group or a trialkylsilyl group, R 4 is a hydrogen atom or a phenyl group.
- a radioiodine-labeled compound represented by the above general formula (1) or a salt thereof is obtained from the compound represented by the above general formula (2) or a salt thereof by a radioiodination reaction.
- a method of manufacturing is provided.
- a novel tau imaging agent capable of selectively imaging a tau protein in a living body by a nuclear medicine technique can be provided.
- FIG. 7 is a diagram showing a synthesis example of 7-iodo-3-phenylbenzo [4,5] imidazo [1,2-a] pyridine (BIP-1) and a labeled precursor compound of radioactive iodine-labeled BIP-1.
- FIG. 3 is a diagram showing a synthesis example of a labeled precursor compound of 3- (4-iodophenyl) benzo [4,5] imidazo [1,2-a] pyridine (BIP-2) and radioactive iodine-labeled BIP-2. .
- FIG. 1 is a diagram showing a synthesis example of 7-iodo-3-phenylbenzo [4,5] imidazo [1,2-a] pyridine (BIP-1) and a labeled precursor compound of radioactive iodine-labeled BIP-1.
- FIG. 3 is a diagram showing a synthesis example of a labeled precursor compound of 3- (4-iodophenyl) benzo [
- FIG. 7 is a diagram showing a synthesis example of a labeled precursor compound of 7-iodobenzo [4,5] imidazo [1,2-a] pyridine (BIP-3) and radioactive iodine-labeled BIP-3.
- FIG. 3 is a diagram showing a synthesis example of a labeled precursor compound of 3-iodobenzo [4,5] imidazo [1,2-a] pyridine (BIP-4) and radioactive iodine-labeled BIP-4. It is a figure which shows the label
- FIG. 4 is a diagram showing a synthesis example of (4- [ 125 I] iodophenyl) benzo [4,5] imidazo [1,2-a] pyridine ([ 125 I] BIP-2), where C is 7- [ 125 I FIG.
- FIG. 3 is a diagram showing a synthesis example of iodobenzo [4,5] imidazo [1,2-a] pyridine ([ 125 I] BIP-3), where D is 3- [ 125 I] iodobenzo [4,5] imidazo [
- FIG. 2 is a diagram showing a synthesis example of 1,2-a] pyridine ([ 125 I] BIP-4). It is a figure which shows the result of the in vitro autoradiography using the autopsy brain tissue of an Alzheimer's disease patient.
- E shows the results of evaluating the binding affinity of radioiodine-labeled BIP-1 using brain tissue sections of the temporal lobe.
- F shows the results of evaluating the binding affinity of [ 125 I] BIP-1 using frontal lobe brain tissue sections.
- G shows the results of evaluating the binding affinity of [ 125 I] BIP-2 using brain tissue sections of temporal lobes.
- H shows the results of evaluating the binding affinity of [ 125 I] BIP-2 using brain tissue sections of the frontal lobe.
- I shows the results of evaluating the binding affinity of [ 125 I] BIP-3 using brain tissue sections of the temporal lobe.
- J shows the results of evaluating the binding affinity of [ 125 I] BIP-3 using brain tissue sections from the frontal lobe.
- K shows the results of evaluating the binding affinity of [125 I] BIP-4 using brain tissue sections of the temporal lobe.
- L shows the results of evaluating the binding affinity of [ 125 I] BIP-4 using brain tissue sections of the frontal lobe.
- FIG. 6I It is a figure which shows the result of having evaluated the binding affinity of [ 125I ] BIP-3 using the brain tissue section
- the “radioactive iodine” is not particularly limited as long as it is a radioactive isotope of iodine, but is preferably a radionuclide used for nuclear medicine imaging such as single photon emission computed tomography (SPECT), more preferably. 123 I, 124 I, 125 I or 131 I, and 123 I is more preferable for nuclear medicine imaging.
- SPECT single photon emission computed tomography
- the “radioactive phenyl group” may be any substituent in which at least one hydrogen atom of the phenyl group is substituted with a radioactive iodine atom, and one hydrogen atom of the phenyl group is a radioactive iodine.
- a monoiodinated phenyl group substituted with an atom is preferred, and more preferred is a phenyl iodide group in which the hydrogen atom at the 2-position, 3-position or 4-position of the phenyl group is substituted with a radioactive iodine atom, and the 4-position of the phenyl group A substituent in which the hydrogen atom is substituted with a radioactive iodine atom (a radioactive 4-iodophenyl group) is more preferable.
- the radioactive iodine-labeled compound represented by the general formula (1) may form a salt, such as an acid addition salt such as an inorganic acid salt (for example, hydrochloride, sulfate, hydrobromic acid). Salts, phosphates, etc.), organic acid salts (eg acetate, trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate, oxalic acid Salt, methanesulfonate, p-toluenesulfonate, etc.). Further, the compound represented by the general formula (1) or a salt thereof may be a hydrate.
- an acid addition salt such as an inorganic acid salt (for example, hydrochloride, sulfate, hydrobromic acid). Salts, phosphates, etc.), organic acid salts (eg acetate, trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate,
- radioactive iodine-labeled compound examples include the following compounds. Radioactive iodine-labeled 7-iodo-3-phenylbenzo [4,5] imidazo [1,2-a] pyridine (in the above general formula (1), R 1 is a radioactive iodine atom, R 2 is a phenyl group Some radioactive iodine-labeled compounds) Radioactive iodine-labeled 3- (4-iodophenyl) benzo [4,5] imidazo [1,2-a] pyridine (in the above general formula (1), R 1 is a hydrogen atom and R 2 is radioactive 4- Radioactive iodine-labeled compounds that are phenyl iodide groups) Radioactive iodine-labeled 7-iodobenzo [4,5] imidazo [1,2-a] pyridine (in the above general formula (1), R 1 is a radioactive iodine atom and R 2
- Radioactive iodine-labeled 3-iodobenzo [4,5] imidazo [1,2-a] pyridine (in the above general formula (1), R 1 is a hydrogen atom, and R 2 is a radioactive iodine atom, a radioactive iodine-labeled compound )
- the radioactive iodine labeling compound represented by the general formula (1) or a salt thereof can be obtained by performing a radioiodination reaction using the compound represented by the general formula (2) or a salt thereof.
- examples of the trialkylstannyl group include a tri (C1-C6 alkyl) stannyl group, and a tributylstannyl group is more preferable.
- examples of the trialkylsilyl group include a tri (C1-C6 alkyl) silyl group, and a trimethylsilyl group is more preferable.
- the “trialkylstannylated phenyl group” may be a substituent in which at least one hydrogen atom of the phenyl group is substituted with a trialkylstannyl group.
- a phenyl group in which an atom is substituted with a trialkylstannyl group is preferred, more preferably a trialkylstannylated phenyl in which a hydrogen atom at the 2-position, 3-position or 4-position of the phenyl group is substituted with a trialkylstannyl group
- a substituent in which the hydrogen atom at the 4-position of the phenyl group is substituted with a trialkylstannyl group (4-trialkylstannylated phenyl group) is more preferable.
- the “trialkylsilylated phenyl group” may be a substituent in which at least one hydrogen atom of the phenyl group is substituted with a trialkylsilyl group.
- a phenyl group substituted with a trialkylsilyl group is preferred, more preferably a trialkylsilylated phenyl group in which a hydrogen atom at the 2-position, 3-position or 4-position of the phenyl group is substituted with a trialkylsilyl group,
- a substituent in which the hydrogen atom at the 4-position of the group is substituted with a trialkylsilyl group (4-trialkylsilylated phenyl group) is more preferable.
- the compound represented by the general formula (2) may form a salt.
- a salt similar to the salt that can be formed by the radioactive iodine-labeled compound represented by the general formula (1) can be employed.
- the compound represented by the general formula (2) can be prepared, for example, according to the scheme shown in FIGS.
- the radioiodination reaction can be carried out by allowing a radioalkali metal iodide salt to act on the compound represented by the general formula (2) or a salt thereof.
- the radioactive alkali metal iodide salt may be a salt of radioactive iodine and an alkali metal, and examples thereof include radioactive sodium iodide and radioactive potassium iodide.
- the reaction between the compound represented by the general formula (2) and the radioactive alkali metal iodide is carried out under acidic conditions and further by reacting with an oxidizing agent.
- an oxidizing agent chloramine-T, hydrogen peroxide, peracetic acid or the like is used.
- radioiodine labeled compound of the general formula (1) When the obtained radioiodine labeled compound of the general formula (1) is used as a radiopharmaceutical, unreacted radioiodine ions and insoluble impurities are purified by membrane filters, columns packed with various packing materials, HPLC, etc. It is desirable to do.
- the radiopharmaceutical according to the present invention can be defined as a formulation containing a radioiodine-labeled compound represented by the above general formula (1) or a salt thereof in a form suitable for administration into a living body.
- This radiopharmaceutical can be prepared as a liquid in which the radioiodine-labeled compound of the above general formula (1) obtained above is blended in water or physiological saline adjusted to an appropriate pH or Ringer's solution, if desired.
- the concentration of the present radioiodine labeled compound is preferably not more than a concentration at which the stability of the blended radioiodine labeled compound is obtained.
- the administration form of the radiopharmaceutical according to the present invention is preferably an injection, and the dose is not particularly limited as long as it is a concentration sufficient to image the distribution of the administered compound.
- the distribution of the present radioactive iodine-labeled compound administered to a living body can be imaged by a known method.
- the image is obtained using single photon emission computed tomography (SPECT).
- SPECT single photon emission computed tomography
- Can be The tau protein can be imaged from the image thus obtained, and for example, Alzheimer's disease can be diagnosed noninvasively.
- BIP-1 7-iodo-3-phenylbenzo [4,5] imidazo [1,2-a] pyridine
- BIP-2 3- (4-iodophenyl) benzo [4,5] imidazo [1,2- a] pyridine
- BIP-3 7-iodobenzo [4,5] imidazo [1,2-a] pyridine
- BIP-4 3-iodobenzo [4,5] imidazo [1,2-a] pyridine [ 125 I]
- BIP ⁇ 1 7- [ 125 I] iodo-3-phenylbenzo [4,5] imidazo [1,2-a] pyridine [ 125 I]
- BIP-2 3- (4- [ 125 I] iodophenyl) benzo [4,5] imidazo [1,2-a] pyridine [ 125 I]
- BIP-3 7- [ 125 I] iodobenzo [4,5] imidazo [1,2-a] pyridine [ 125 I]
- BIP-3 7-
- the medium pressure preparative liquid chromatography system includes an automatically set medium pressure preparative liquid chromatograph system manufactured by Yamazen Co., Ltd. (EPCLC-W-Prep 2XY; liquid feed pump (mixer built-in): No.
- detector wavelength (Fixed type): prep UV-254W, fraction collector: FR-260
- HI-FLASH COLUMN fill: silica gel SiOH, pore size: 60 ⁇ , particle size: 40 ⁇ m, column size: L or 2 L
- INJECT COLUMN fill: silica gel SiOH, pore size: 60 ⁇ , particle size: 40 ⁇ m, column size: M or L
- NMR was measured using a JNM-AL400 NMR apparatus manufactured by JEOL Ltd. with tetramethylsilane as an internal standard substance.
- reaction solution was cooled to ⁇ 78 ° C., and a hexane solution (15.0 mL) of carbon tetrabromide (6.30 g, 18.0 mmol) was then added dropwise little by little, followed by stirring for 50 minutes.
- Purified water was added under ice cooling to stop the reaction, followed by extraction with ethyl acetate (100 mL ⁇ 2).
- the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 2 Synthesis of BIP-1 (Compound 10) A non-radioactive compound of BIP-1 (Compound 10) was obtained according to the scheme shown in FIG. Compound 9 (24.7 mg, 0.0463 mmol) obtained by the method shown in Example 1 was dissolved in chloroform (15.0 mL), and iodine solution in chloroform (50.0 mg / mL) was added at room temperature. For 1.5 hours. The reaction was quenched with a saturated aqueous sodium hydrogen sulfite solution, followed by extraction with chloroform (50.0 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 4 Synthesis of BIP-2 (Compound 14) A non-radioactive compound of BIP-2 (Compound 14) was obtained according to the scheme shown in FIG. Compound 13 (70.0 mg, 0.130 mmol) obtained by the method shown in Example 3 was dissolved in chloroform (30.0 mL), and 5.00 mL of a chloroform solution of iodine (50.0 mg / mL) was added to room temperature. For 1 hour. The reaction was stopped with a saturated aqueous sodium hydrogen sulfite solution, followed by extraction with chloroform (100 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 6 Synthesis of BIP-3 (Compound 17) A non-radioactive compound of BIP-3 (Compound 17) was obtained according to the scheme shown in FIG.
- Compound 16 (510 mg, 1.11 mmol) obtained by the method shown in Example 5 was dissolved in chloroform (100 mL), 10.0 mL of iodine in chloroform (50.0 mg / mL) was added, and the mixture was stirred at room temperature for 11 hours. did. The reaction was stopped with a saturated aqueous sodium hydrogen sulfite solution, followed by extraction with chloroform (100 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 8 Synthesis of BIP-4 (Compound 19) A non-radioactive compound of BIP-4 (Compound 19) was obtained according to the scheme shown in FIG. Compound 18 (140 mg, 0.310 mmol) obtained by the method shown in Example 7 was dissolved in chloroform (30.0 mL), and 5.00 mL of a chloroform solution of iodine (50.0 mg / mL) was added. Stir for 5 hours. The reaction was stopped with a saturated aqueous sodium hydrogen sulfite solution, followed by extraction with chloroform (100 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 9 [125 I] along the scheme shown in the synthesis diagram 5 of BIP-1 ⁇ 4, to obtain a [125 I] BIP-1 ⁇ 4. Specifically, [ 125 I] sodium iodide (3.7 to 7.4 MBq, specific activity 81.4 TBq / mmol) was added, and 1 mol / L hydrochloric acid (100 ⁇ L), 3% (v / v) excess was added.
- an ethanol solution of compound 9 obtained by the method shown in Example 1 an ethanol solution of compound 9 obtained by the method shown in Example 1, compound 16 obtained by the method shown in Example 5, compound 18 obtained by the method shown in Example 7, Alternatively, 0.1% (v / v) acetic acid-containing methanol solution (1.00 mg / mL, 200 ⁇ L) of Compound 13 obtained by the method shown in Example 3 was added. After reacting at room temperature for 40 minutes, a saturated sodium hydrogensulfite aqueous solution (200 ⁇ L) was added as a reducing agent to stop the reaction. Saturated aqueous sodium hydrogen carbonate solution (200 ⁇ L) was added to neutralize the reaction mixture, and the mixture was extracted with ethyl acetate.
- the mobile phase and retention time of reverse phase HPLC are shown in Table 1. After dehydrating through a column filled with anhydrous sodium sulfate, the solvent was distilled off. Each compound of [ 125 I] BIP-1 to 4 was obtained with a radiochemical yield of 45 to 85% and a radiochemical purity of 99% or more.
- Example 10 Synthesis of [ 123 I] BIP-1 to 4
- 37-111 MBq of [ 123 I] sodium iodide (111 MBq / 10 ⁇ L) was used instead of [ 125 I] sodium iodide. Obtained [ 123 I] BIP-1 to 4 in the same manner.
- FIGS. 6E and F show the results using [ 125 I] BIP-1
- FIGS. 6G and H show the results using [ 125 I] BIP-2
- FIGS. 6I and J show [ 125 I].
- the results using BIP-3 are shown
- FIGS. 6K and 6L show the results using [ 125 I] BIP-4.
- 6E, G, I, and K show the results using the temporal lobe brain tissue section
- FIGS. 6F, H, J, and L show the results using the frontal brain tissue section.
- both [ 125 I] BIP-1 and [ 125 I] BIP-2 did not accumulate radioactivity in the brain tissue sections of the frontal lobe.
- Histofine Simple Stain MAX-PO (MULTI) (manufactured by Nichirei Bioscience) was reacted at room temperature for 30 minutes and then washed with PBS-Tween 20 (3 minutes ⁇ 3) and TBS (5 minutes ⁇ 1). Finally, it was reacted with the DAB solution at room temperature for 1 minute. The reaction was stopped by washing with distilled water (1 minute ⁇ 1). After enclosing the brain tissue section, the brain tissue section was observed with a microscope (BZ-9000 manufactured by Keyence Corporation).
- FIG. 7M shows the result of immunostaining of tau antibody
- FIG. 7O shows the result of immunostaining of A ⁇ antibody
- FIG. 7N is an enlarged image of FIG. 6I.
- Table 3 shows the results of an experiment of in vivo radioactivity distribution of [ 125 I] BIP-3.
- the numerical values shown according to the time after administration are the average value of% ID for the stomach and thyroid gland, the average value of% ID / g for the other tissues, and the standard deviation (SD) in parentheses. Show. The uptake into the kidney 2 minutes after administration (23.7% ID / g) and the uptake into the liver (19.9% ID / g) were comparable. In addition, uptake into the intestine 60 minutes after administration was 29.4% ID / g, and the behavior of being gradually excreted from the liver into the intestine was shown. In addition, the thyroid uptake was 0.22% ID even 60 minutes after administration, and the accumulation in the thyroid accompanying deiodination was relatively low, suggesting that no significant deiodination occurred in vivo. It was.
- the protein was denatured by adding methanol twice the volume of the obtained plasma, and centrifuged at 4 ° C. and 4000 ⁇ g for 5 minutes.
- the obtained supernatant was analyzed by reverse phase HPLC through a Cosmonic Filter (S) (0.45 ⁇ m, 4 mm) (Nacalai Tesque, Inc.).
- the HPLC analysis conditions were the same as those used in Example 9.
- radioactive iodine-labeled compound according to the present invention can selectively and noninvasively image brain tau protein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
・放射性ヨウ素標識7-ヨード-3-フェニルベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がフェニル基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識3-(4-ヨードフェニル)ベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1が水素原子であり、R2が放射性4-ヨウ化フェニル基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2が水素原子である放射性ヨウ素標識化合物)
・放射性ヨウ素標識3-ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1が水素原子であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
BIP-1:7-ヨード-3-フェニルベンゾ[4,5]イミダゾ[1,2-a]ピリジン
BIP-2:3-(4-ヨードフェニル)ベンゾ[4,5]イミダゾ[1,2-a]ピリジン
BIP-3:7-ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
BIP-4:3-ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[125I]BIP-1:7-[125I]ヨード-3-フェニルベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[125I]BIP-2:3-(4-[125I]ヨードフェニル)ベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[125I]BIP-3:7-[125I]ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[125I]BIP-4:3-[125I]ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[123I]BIP-1:7-[123I]ヨード-3-フェニルベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[123I]BIP-2:3-(4-[123I]ヨードフェニル)ベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[123I]BIP-3:7-[123I]ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[123I]BIP-4:3-[123I]ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン
質量分析は、大気圧化学イオン化(APCI-MS)法では、株式会社島津製作所製のLCMS-2010EVを用い、電子イオン化質量分析(EI-MS)では、日本電子株式会社製のGCmate IIを用いて測定した。
また、本実施例において、「室温」は25℃である。
各化合物の合成例において、化合物合成における各ステップは、必要に応じて複数回繰り返し行い、他の合成において中間体等として用いる際に必要な量を確保した。
放射能の測定にはパーキンエルマー株式会社製のWallac WIZARD 1470を用いた。
図1に示すスキームに沿って、放射性ヨウ素標識BIP-1の標識前駆体化合物(化合物9)を得た。
ジメチルアミノエタノール(DMAE,1.50mL,15.0mmol)をヘキサン(20.0mL)に溶解し,氷冷下で撹拌した。n-ブチルリチウム(2.5mol/Lヘキサン溶液,12.0mL,30.0mmol)を氷冷下で少しずつ滴下し、そのまま30分間撹拌した。4-フェニルピリジン(776mg,5.00mmol)のヘキサン溶液(30.0mL)を氷冷下で少しずつ滴下し、そのまま1時間撹拌した。反応溶液を-78℃に冷却した後、四臭化炭素(6.30g,18.0mmol)のヘキサン溶液(15.0mL)を少しずつ滴下し、そのまま50分間撹拌した。氷冷下で精製水を加えて反応を停止した後、酢酸エチル(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物7を収量645mg(収率55.1%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.38(d,J=5.2Hz,1H),7.66-7.67(m,1H),7.56-7.58(m,2H),7.42-7.49(m,4H)。
化合物7(645mg,2.75mmol)をキシレン(30.0mL)に溶解し、2,4-ジブロモアニリン(690mg,2.75mmol)、ヨウ化銅(I)(105mg,0.550mmol)、炭酸セシウム(2.67g,8.26mmol)及び1,10-フェナントロリン(198mg,1.10mmol)を加えた後、撹拌下、24時間加熱還流させた。反応溶液を室温に戻し、酢酸エチル(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物8を収量78.4mg(収率8.80%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.47(d,J=7.2Hz,1H),8.08(s,1H),7.88(s,1H),7.77(d,J=8.7Hz,1H),7.72(d,J=7.2Hz,2H),7.45-7.55(m,4H),7.19(d,J=7.0Hz,1H)。
化合物8(95.0mg,0.294mmol)を1,4-ジオキサン(20.0mL)に溶解し、ビス(トリブチルスズ)(295μL,0.588mmol)、テトラキストリフェニルホスフィンパラジウム(146mg,0.126mmol)及びトリエチルアミン(16.0mL)を加えて、撹拌下、3時間加熱還流させた。反応終了後、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/2(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物9を収量26.7mg(収率17.0%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.48(d,J=7.3Hz,1H),8.08(s,1H),7.87-7.89(m,2H),7.72(d,J=7.5Hz,2H),7.44-7.53(m,4H),7.12(dd,J=7.2,1.7Hz,1H),0.87-1.63(m,27H)。
図1に示すスキームに沿って、BIP-1の非放射性化合物(化合物10)を得た。
実施例1に示す方法で得られた化合物9(24.7mg,0.0463mmol)をクロロホルム(15.0mL)に溶解し、ヨウ素のクロロホルム溶液(50.0mg/mL)を1.00mL加えて室温で1.5時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止させた後、クロロホルム(50.0mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/2(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物10(BIP-1)を収量10.3mg(収率60.2%)で得た。また、BIP-1は、4-フェニルピリジンからの4段階の反応で0.496%の収率で得られた。
1H-NMR(400MHz,DMSO-d6)δ 9.18(d,J=7.3Hz,1H),8.19-8.22(m,2H),7.93-7.99(m,3H),7.66(dd,J=8.4,1.4Hz,1H),7.51-7.57(m,2H),7.46-7.51(m,2H)。
HRMS(EI)m/z calcd for C17H11IN2(M+)369.9967,found 369.9960。
図2に示すスキームに沿って、放射性ヨウ素標識BIP-2の標識前駆体化合物(化合物13)を得た。
2-ブロモアニリン(855mg,5.00mmol)をキシレン(5.00mL)に溶解し、2,4-ジブロモピリジン(1.41g,6.00mmol)、ヨウ化銅(I)(191mg,1.00mmol)、炭酸セシウム(4.89g,15.0mmol)及び1,10-フェナントロリン(360mg,2.00mmol)を加えた後、撹拌下、9.5時間加熱還流させた。反応溶液を室温に戻し、酢酸エチル(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物11を収量615mg(収率50.0%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.32(d,J=7.3Hz,1H),7.94(d,J=8.2Hz,1H),7.86-7.90(m,2H),7.56(dd,J=7.3,7.3Hz,1H),7.41(dd,J=7.3,7.3Hz,1H),6.96(dd,J=7.1,1.8Hz,1H)。
化合物11(123mg,0.500mmol)をトルエン(5.00mL)及びエタノール(5.00mL)に溶解し,4-ブロモベンゼンボロン酸(100mg,0.500mmol)、テトラキストリフェニルホスフィンパラジウム(58.0mg,5.00×10-2mmol)及び炭酸カリウム(14.0mg,0.100mmol)を加えた後、撹拌下、11時間加熱還流させた。反応溶液を室温に戻した後、酢酸エチル(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物12を収量90.0mg(収率55.9%)で得た。
1H-NMR(400MHz,DMSO-d6)δ 9.18(d,J=7.1Hz,1H),8.35(d,J=8.0Hz,1H),8.02(s,1H),7.91(d,J=7.6Hz,2H),7.82(d,J=8.5Hz,1H),7.74(d,J=7.3Hz,2H),7.52(dd,J=7.3,7.3Hz,1H),7.37-7.42(m,2H)。
化合物12(90.0mg,0.280mmol)を1,4-ジオキサン(5.00mL)に溶解し、ビス(トリブチルスズ)(280μL,0.560mmol)、テトラキストリフェニルホスフィンパラジウム(139mg,0.120mmol)及びトリエチルアミン(5.00mL)を加えて、撹拌下、5時間加熱還流させた。反応終了後、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物13を収量70.0mg(収率47.0%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.46(d,J=7.1Hz,1H),7.87-7.95(m,3H),7.50-7.68(m,5H),7.36(dd,J=8.0,8.0Hz,1H),7.14(dd,J=7.1,1.1Hz,1H)。
図2に示すスキームに沿って、BIP-2の非放射性化合物(化合物14)を得た。
実施例3に示す方法で得られた化合物13(70.0mg,0.130mmol)をクロロホルム(30.0mL)に溶解し,ヨウ素のクロロホルム溶液(50.0mg/mL)を5.00mL加えて室温で1時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止させた後、クロロホルム(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物14(BIP-2)を収量10.0mg(収率20.6%)で得た。また、化合物BIP-2は、2-ブロモアニリンからの4段階の反応で2.71%の収率で得られた。
1H-NMR(400MHz,DMSO-d6)δ 9.60(d,J=7.1Hz,1H),8.63(d,J=8.5Hz,1H),8.33(s,1H),8.00-8.04(m,3H),7.95(d,J=8.2Hz,1H),7.86(d,J=8.7Hz,2H),7.80(dd,J=7.1,7.1Hz,1H),7.68(dd,J=7.3,7.3Hz,1H)。
HRMS(EI)m/z calcd for C17H11IN2(M+)369.9967,found 369.9970。
図3に示すスキームに沿って、放射性ヨウ素標識BIP-3の標識前駆体化合物(化合物16)を得た。
2,5-ジブロモアニリン(1.24g,5.00mmol)をキシレン(5.00mL)に溶解し、2-ブロモピリジン(585μL,6.00mmol)、ヨウ化銅(I)(190mg,1.00mmol)、炭酸セシウム(4.89g,15.0mmol)及び1,10-フェナントロリン(360mg,2.00mmol)を加えた後、撹拌下、22時間加熱還流させた。反応溶液を室温に戻し、酢酸エチル(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/1(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物15を収量834mg(収率67.8%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 9.12(d,J=6.7Hz,1H),8.31(d,J=8.4Hz,1H),8.01(d,J=1.5Hz,1H),7.69(d,J=9.3Hz,1H),7.60-7.64(m,1H),7.52(dd,J=8.7,1.7Hz,1H),7.06(dd,J=6.7,6.7Hz,1H)。
化合物15(834mg,3.39mmol)を1,4-ジオキサン(10.0mL)に溶解し、ビス(トリブチルスズ)(3.40mL,6.78mmol)、テトラキストリフェニルホスフィンパラジウム(1.69g,1.46mmol)及びトリエチルアミン(10.0mL)を加えて、撹拌下、6時間加熱還流させた。反応終了後、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物16を収量510mg(収率32.8%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.46(d,J=7.0Hz,1H),8.08(s,1H),7.88(d,J=8.1Hz,1H),7.69(d,J=9.3Hz,1H),7.45(d,J=8.1Hz,1H),7.40-7.42(m,1H),6.84(dd,J=7.0,7.0Hz,1H),0.87-1.64(m,27H)。
図3に示すスキームに沿って、BIP-3の非放射性化合物(化合物17)を得た。
実施例5に示す方法で得られた化合物16(510mg,1.11mmol)をクロロホルム(100mL)に溶解し、ヨウ素のクロロホルム溶液(50.0mg/mL)を10.0mL加えて室温で11時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止させた後、クロロホルム(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/1(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物17(BIP-3)を収量210mg(収率64.2%)で得た。また、BIP-3は、2,5-ジブロモアニリンからの3段階の反応で14.3%の収率で得られた。
1H-NMR(400MHz,DMSO-d6)δ 9.10(dd,J=6.7,0.9Hz,1H),8.17-8.19(m,2H),7.59-7.70(m,3H),7.05(dd,J=6.7,6.7Hz,1H)。
HRMS(EI)m/z calcd for C11H7IN2(M+)293.9654,found 293.9660。
図4に示すスキームに沿って、放射性ヨウ素標識BIP-4の標識前駆体化合物(化合物18)を得た。
実施例3に示す方法で得られた化合物11(182mg,0.740mmol)を1,4-ジオキサン(10.0mL)に溶解し、ビス(トリブチルスズ)(741μL,1.48mmol)、テトラキストリフェニルホスフィンパラジウム(368mg,0.320mmol)及びトリエチルアミン(10.0mL)を加えて、撹拌下、19.5時間加熱還流させた。反応終了後に溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物18を収量140mg(収率41.3%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.29(d,J=6.6Hz,1H),7.76-7.86(m,3H),7.44(dd,J=8.2,8.2Hz,1H),7.26(dd,J=8.0,8.0Hz,1H),6.82(d,J=6.6Hz,1H),0.79-1.60(m,27H)。
図4に示すスキームに沿って、BIP-4の非放射性化合物(化合物19)を得た。
実施例7に示す方法で得られた化合物18(140mg,0.310mmol)をクロロホルム(30.0mL)に溶解し,ヨウ素のクロロホルム溶液(50.0mg/mL)を5.00mL加えて室温で1.5時間撹拌した.飽和亜硫酸水素ナトリウム水溶液で反応を停止させた後、クロロホルム(100mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/へキサン(1/4(体積比))を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物19を収量50.0mg(収率55.7%)で得た。また、BIP-4は、2-ブロモアニリンからの3段階の反応で11.5%の収率で得られた。
1H-NMR(400MHz,DMSO-d6)δ 8.91(d,J=7.3Hz,1H),8.31(d,J=8.2Hz,1H),8.18(s,1H),7.81(d,J=8.2Hz,1H),7.53(ddd,J=7.1,7.1,0.9Hz,1H),7.39(ddd,J=8.2,8.2,0.9,1H),7.28(dd,J=7.1,1.6Hz,1H)。
HRMS (EI)m/z calcd for C11H7IN2 (M+)293.9654,found 293.9652。
図5に示すスキームに沿って、[125I]BIP-1~4を得た。具体的には、[125I]ヨウ化ナトリウム(3.7~7.4MBq,比放射能81.4TBq/mmol)を添加し、1mol/L塩酸(100μL)、3%(v/v)過酸化水素水溶液(100μL)に、実施例1に示す方法で得られた化合物9、実施例5に示す方法で得られた化合物16、実施例7に示す方法で得られた化合物18のエタノール溶液、又は、実施例3に示す方法で得られた化合物13の0.1%(v/v)酢酸含有メタノール溶液(1.00mg/mL,200μL)を加えた。室温で40分間反応させた後、還元剤として飽和亜硫酸水素ナトリウム水溶液(200μL)を加え、反応を停止させた。飽和炭酸水素ナトリウム水溶液(200μL)を加え、反応液を中和した後、酢酸エチルで抽出した。無水硫酸ナトリウムを充填したカラムを通し脱水した後、溶媒を留去した。実施例2、4、6、8に示す方法で得られた対応する非放射性化合物BIP-1~4を標品として、逆相高速液体クロマトグラフィー(HPLC)を用いて精製し、酢酸エチルで抽出した。HPLCは株式会社島津製作所製LC-20ADを使用し、検出器として紫外スペクトル検出器SPD-20Aと日立アロカメディカル株式会社製シンチレーションサーベイメーターTCS-172を使用した。HPLC用カラムにはナカライテスク株式会社製COSMOSIL 5C18-AR-II(4.6mmI.D.×150mm)を使用した。逆相HPLCの移動相及び保持時間は表1に示す。無水硫酸ナトリウムを充填したカラムを通し脱水した後、溶媒を留去した。[125I]BIP-1~4の各化合物を放射化学的収率45~85%,放射化学的純度99%以上で得た。
実施例9において、[125I]ヨウ化ナトリウムに代えて[123I]ヨウ化ナトリウム(111MBq/10μL)を37~111MBq使用した以外は、同様にして、[123I]BIP-1~4を得た。
(1)インビトロオートラジオグラフィー
アルツハイマー病(AD)患者剖検脳組織切片(76歳,男性,前頭葉部位と、側頭葉部位のもの,6μm)は、京都大学医学研究科より提供されたものを使用した。キシレン洗浄(15分×2)、エタノール(1分×2)、90体積%エタノール水溶液(1分×1)、80体積%エタノール水溶液(1分×1)、70体積%エタノール水溶液(1分×1)及び精製水洗浄(2.5分×2)をすることで脱パラフィン処理を行った。実施例9に示す方法で得られた[125I]BIP-1~4の10体積%あるいは50体積%エタノール水溶液(370kBq/mL)を添加し、室温で2時間インキュベートした。50体積%エタノール水溶液(2時間×1)で洗浄後、イメージングプレート(富士フィルム株式会社製BAS-SR2025)に12時間露光させ、バイオイメージングアナライザー(富士フィルム株式会社製バイオーメージングアナライザーBAS-5000)にて分析を行った。定量解析には富士フィルム株式会社製Multi Gaugeを使用した。
以上の結果より、[125I]BIP-1~4は、Aβに比べてタウに対する選択的結合性を有しており、さらに、白質への非特異的集積が低かったことから、タウイメージングプローブの骨格として有望である可能性が示された。
オートラジオグラフィーで使用した脳切片に近接する切片を用いて,老人斑(SP)及び神経原線維変化(NFT)の染色を行った。SPの免疫染色における1次抗体には、抗Aβ1-42モノクローナル抗体(BC05,WAKO社製)を、NFTの免疫染色における抗体には、抗リン酸化タウモノクローナル抗体(AT8,Thermo Scientfic社製)を用いた。キシレン洗浄(15分×2)、エタノール(1分×2)、90体積%エタノール水溶液(1分×1)、80体積%エタノール水溶液(1分×1)、70体積%エタノール水溶液(1分×1)及び精製水洗浄(2.5分×2)することで脱パラフィン処理を行った。抗原の賦活化には0.01mol/Lクエン酸緩衝液(pH6.0)中におけるオートクレーブ(15分)及び蟻酸処理(5分)を行った。流水で洗浄(5分)した後、PBS-Tween20(2分×1)で洗浄した。1次抗体溶液と室温で1時間反応させた後、PBS-Tween20(5分×3)で洗浄した。ヒストファイン シンプルステイン MAX-PO(MULTI)(ニチレイバイオサイエンス社製)と室温で30分間反応させた後、PBS-Tween20(3分×3)およびTBS(5分×1)で洗浄した。最後に、DAB溶液と室温で1分間反応させた。蒸留水(1分×1)で洗浄し反応を停止させた。脳組織切片を封入した後に顕微鏡(株式会社キーエンス製BZ-9000)で観察した。
実施例9に示す方法で得られた[125I]BIP-1~4を10体積%エタノール及び0.1体積%Tween80を含む生理食塩水で希釈した。1群5匹の5週齢ddY系雄性マウス(26-28g)に、尾静脈より1匹あたり25.0-37.5kBq(100μL)の[125I]BIP-1~4をそれぞれ投与し、2、10、30、60分後に屠殺、採血後、脳を取り出し、重量と放射能を測定した。また、[125I]BIP-3に関しては、主要な臓器を摘出し、重量と放射能を測定した。
ddYマウス(5週齢、体重25-28g)をイソフルランで麻酔して心臓採血を行った。採取した血液は4000×gで10分間遠心分画し、上清を回収した。実施例9に示す方法で得られた[125I]BIP-3(188kBq、10.0μL、エタノール溶液)及びマウス血漿サンプル(200μL)を混合した。37℃で1時間インキュベートし、アセトニトリル(400μL)を加えてから4000×gで10分間遠心分画した。上清を回収してCosmonice Filter(S)(0.45μm、4mm)(ナカライテスク株式会社)で処理した後、逆相HPLCで分析した。なお、HPLCの分析条件は、実施例9で使用した条件と同様である。
1-オクタノール(3.00mL)及び0.1mol/Lリン酸緩衝液(pH7.4,3.00mL)が入った遠心管に実施例9に示す方法で得られた[125I]BIP-1~4(125kBq)を加え、2分間vortexした後、4,000×gで10分間遠心分離した。各層から500μLずつ溶液を採取した後、それぞれの放射能を測定し、1-オクタノール/リン酸緩衝液の放射能比から分配係数を求めた。結果を表4に示す。
正常マウスとして5週齢、雄性のddYマウスを用いた。実施例10に示す方法で得られた[123I]BIP-3の0.1体積%Tween80及び10体積%エタノールを含有した生理食塩水を尾静脈より投与した(3.70MBq、100μL)。投与後2分、10分、30分後に屠殺し、ヘパリンナトリウム注(ニプロファーマ社製)で内壁をコーティングした試験管に血液を採取した。血液は放射能を測定後4℃,4000×gで5分間遠心し、血漿と細胞成分に分離した。得られた血漿の2倍の体積のメタノールを加えてタンパクを変性させ、4℃、4000×gで5分間遠心した。得られた上清はCosmonice Filter(S)(0.45μm,4mm)(ナカライテスク株式会社)を通し,逆相HPLCにて分析した。なお、HPLCの分析条件は、実施例9で使用した条件と同様である。
正常マウスとして5週齢、雄性のddYマウスを用いた。実施例10に示す方法で得られた[123I]BIP-3の0.1体積%Tween80及び10体積%エタノールを含有した生理食塩水を尾静脈より投与し(3.70MBq,100μL)、2分後に屠殺、脳を摘出してメタノール(2.00mL)及びTBS(2.00mL)中でホモジナイズし、4000×g、4℃で10分間遠心分離後、上清を採取した。得られた上清はCosmonice Filter(S)(0.45μm,4mm)(ナカライテスク株式会社)を通し,逆相HPLCにて分析した。なお、HPLCの分析条件は、実施例9で使用した条件と同様である。
Claims (8)
- 前記放射性ヨウ化フェニル基は、フェニル基の4位の水素原子が放射性ヨウ素原子で置換された置換基である、請求項1に記載の放射性ヨウ素標識化合物又はその塩。
- 前記放射性ヨウ素原子が、123I、124I、125I又は131Iである、請求項1又は2に記載の放射性ヨウ素標識化合物又はその塩。
- 請求項1乃至3いずれか1項に記載された放射性ヨウ素標識化合物又はその塩を含む、放射性医薬。
- 単光子放出コンピューター断層撮影(SPECT)に用いられる、請求項4に記載の放射性医薬。
- 請求項1乃至3いずれか1項に記載された放射性ヨウ素標識化合物又はその塩を含む、アルツハイマー病診断剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177015116A KR20170123306A (ko) | 2015-03-04 | 2016-02-24 | 방사성 요오드 표지 피리도[1,2-a]벤조이미다졸 유도체 화합물 |
EP16758812.8A EP3266778A4 (en) | 2015-03-04 | 2016-02-24 | RADIOACTIVE IODINE LABELED PYRIDO[1,2-a]BENZOIMIDAZOLE DERIVATIVE COMPOUND |
CN201680005333.0A CN107207499A (zh) | 2015-03-04 | 2016-02-24 | 经放射性碘标记的吡啶并[1,2‑a]苯并咪唑衍生物化合物 |
CA2973947A CA2973947A1 (en) | 2015-03-04 | 2016-02-24 | Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound |
US15/543,857 US10080812B2 (en) | 2015-03-04 | 2016-02-24 | Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound |
JP2017503433A JP6609866B2 (ja) | 2015-03-04 | 2016-02-24 | 放射性ヨウ素標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 |
AU2016227062A AU2016227062A1 (en) | 2015-03-04 | 2016-02-24 | Radioactive iodine labeled pyrido(1,2-a)benzoimidazole derivative compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015042748 | 2015-03-04 | ||
JP2015-042748 | 2015-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016140118A1 true WO2016140118A1 (ja) | 2016-09-09 |
Family
ID=56848802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/055356 WO2016140118A1 (ja) | 2015-03-04 | 2016-02-24 | 放射性ヨウ素標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10080812B2 (ja) |
EP (1) | EP3266778A4 (ja) |
JP (1) | JP6609866B2 (ja) |
KR (1) | KR20170123306A (ja) |
CN (1) | CN107207499A (ja) |
AU (1) | AU2016227062A1 (ja) |
CA (1) | CA2973947A1 (ja) |
TW (1) | TW201639840A (ja) |
WO (1) | WO2016140118A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012521988A (ja) * | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
JP2013522365A (ja) * | 2010-03-23 | 2013-06-13 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経性疾患の検出のためのイメージング剤 |
WO2013176698A1 (en) * | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
US8476449B2 (en) | 2010-03-01 | 2013-07-02 | Nihon Medi-Physics Co., Ltd. | Radioactive iodine labeled organic compound or salt thereof |
JP2013237655A (ja) | 2012-05-17 | 2013-11-28 | Kyoto Univ | コンフォメーション病診断用分子プローブ |
JP6260967B2 (ja) | 2013-11-06 | 2018-01-17 | 国立大学法人京都大学 | 放射性ヨウ素標識化合物、及び、これを含む放射性医薬 |
-
2016
- 2016-02-24 JP JP2017503433A patent/JP6609866B2/ja not_active Expired - Fee Related
- 2016-02-24 EP EP16758812.8A patent/EP3266778A4/en not_active Withdrawn
- 2016-02-24 CA CA2973947A patent/CA2973947A1/en not_active Abandoned
- 2016-02-24 WO PCT/JP2016/055356 patent/WO2016140118A1/ja active Application Filing
- 2016-02-24 AU AU2016227062A patent/AU2016227062A1/en not_active Abandoned
- 2016-02-24 US US15/543,857 patent/US10080812B2/en not_active Expired - Fee Related
- 2016-02-24 KR KR1020177015116A patent/KR20170123306A/ko unknown
- 2016-02-24 CN CN201680005333.0A patent/CN107207499A/zh active Pending
- 2016-03-02 TW TW105106282A patent/TW201639840A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012521988A (ja) * | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
JP2013522365A (ja) * | 2010-03-23 | 2013-06-13 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経性疾患の検出のためのイメージング剤 |
WO2013176698A1 (en) * | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
Non-Patent Citations (1)
Title |
---|
KENJI MATSUMURA ET AL.: "Development of novel radioiodinated benzoimidazopyridine derivatives for in vivo imaging of tau in Alzheimer's disease brains", ABSTRACTS OF 135TH ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN 2, 5 March 2015 (2015-03-05), pages 258, XP009505689 * |
Also Published As
Publication number | Publication date |
---|---|
EP3266778A1 (en) | 2018-01-10 |
US10080812B2 (en) | 2018-09-25 |
US20180000974A1 (en) | 2018-01-04 |
KR20170123306A (ko) | 2017-11-07 |
JP6609866B2 (ja) | 2019-11-27 |
EP3266778A4 (en) | 2018-11-14 |
CN107207499A (zh) | 2017-09-26 |
CA2973947A1 (en) | 2016-09-09 |
AU2016227062A1 (en) | 2017-08-03 |
TW201639840A (zh) | 2016-11-16 |
JPWO2016140118A1 (ja) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5272110B2 (ja) | 新規アミロイド親和性化合物 | |
US20070258887A1 (en) | Compounds and amyloid probes thereof for therapeutic and imaging uses | |
JP2014074029A (ja) | 神経学的障害を検知するためのイメージング剤 | |
Ono et al. | Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of β-amyloid plaques in Alzheimer’s disease | |
EP2218464A1 (en) | Compounds for non-invasive measurement of aggregates of amyloid peptides | |
Fuchigami et al. | Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT | |
JP5167436B2 (ja) | 新規アミロイド親和性化合物 | |
US8476449B2 (en) | Radioactive iodine labeled organic compound or salt thereof | |
JP6609866B2 (ja) | 放射性ヨウ素標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 | |
JP6609868B2 (ja) | 放射性ハロゲン標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 | |
Cao et al. | Synthesis and preliminary evaluation of 131 I-9-iodovinyl-tetrabenazine targeting vesicular monoamine transporter 2 | |
WO2014132919A1 (ja) | 診断用組成物 | |
JP7284490B2 (ja) | モノアミンオキシダーゼbイメージングプローブ | |
US8802053B2 (en) | Radio-methyl vorozole and methods for making and using the same | |
JP2021102593A (ja) | タウを画像化する新規化合物 | |
WO2014163106A1 (ja) | アセチルコリン小胞トランスポーターの検出に適した化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16758812 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20177015116 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017503433 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2973947 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2016758812 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15543857 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016227062 Country of ref document: AU Date of ref document: 20160224 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |